
AiCuris is a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria. AiCuris‘ mission is the development of innovative drugs against severe and life-threatening infectious diseases with high medical need. AiCuris aims to be THE successful innovator for antiviral and antibacterial therapy.

AiCuris is a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria. AiCuris‘ mission is the development of innovative drugs against severe and life-threatening infectious diseases with high medical need. AiCuris aims to be THE successful innovator for antiviral and antibacterial therapy.
Stage: Clinical-stage biopharmaceutical company
Therapeutic focus: Antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, Hepatitis B/C, multi-resistant bacteria
Founded: 2006 (spin-off from Bayer HealthCare)
Headquarters: Wuppertal, Nordrhein-Westfalen, Germany
Employees: 74
Infectious diseases—antiviral and antibacterial resistance
2006
Biopharmaceuticals
Series B recorded on April 23, 2010